Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156287 | 0.84 | KMT2A (0.48) | KMT2A | |
| SCHEMBL4171464 | 0.72 | ALDH1A1 (0.43) | KMT2AGRIN1GRIN2BIDO1 | |
| SCHEMBL20874815 | 0.66 | GRIN1 (0.56) | GRIN1GRIN2B | |
| SCHEMBL5347308 | 0.66 | KMT2A (0.44) | DBHKMT2ADAO | |
| SCHEMBL17395451 | 0.61 | PIM1 (0.39) | — | |
| SCHEMBL4163334 | 0.61 | ALDH1A1 (0.50) | KMT2A | |
| SCHEMBL20874771 | 0.60 | GRIN1 (0.56) | GRIN1GRIN2B | |
| SCHEMBL4763627 | 0.59 | MEN1 (0.44) | KMT2AGRIN1GRIN2BPARG | |
| SCHEMBL31198448 | 0.59 | KMT2A (0.48) | KMT2A | |
| SCHEMBL1170030 | 0.58 | LMNA (0.63) | KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | TK1, LCK, FYN | DBH 3036/4885KMT2A 2499/4885DAO 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.